Cytotoxicity of the CD3×CD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targeting

Chronic lymphocytic leukemia (CLL) is an immunosuppressive disease characterized by increased infectious morbidity and inferior antitumor activity of immunotherapies. Targeted therapy with Bruton's tyrosine kinase inhibitors (BTKis) or the Bcl-2 inhibitor venetoclax has profoundly improved trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Mhibik, Maissa, Gaglione, Erika M., Eik, David, Herrick, John, Le, Janet, Ahn, Inhye E., Chiu, Christopher, Wielgos-Bonvallet, Monica, Hiemstra, Ida H., Breij, Esther C. W., Chen, Jenny, Reilly, Edward B., Epling-Burnette, Pearlie K., Szafer-Glusman, Edith, Sun, Clare, Wiestner, Adrian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Lymphoid Neoplasia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10388733/
https://www.ncbi.nlm.nih.gov/pubmed/37219524
http://dx.doi.org/10.1182/bloodadvances.2022009517

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10388733/
https://www.ncbi.nlm.nih.gov/pubmed/37219524
http://dx.doi.org/10.1182/bloodadvances.2022009517

Ejemplares similares